Department of Genetics, Cell and Immunobiology, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary.
Department of Rheumatology, Polyclinic of the Hospitaller Brothers of St John of God, Frankel Leó út 54, H-1023 Budapest, Hungary.
Nat Rev Rheumatol. 2014 Jun;10(6):356-64. doi: 10.1038/nrrheum.2014.19. Epub 2014 Feb 18.
The discovery that submicron-sized extracellular vesicles (EVs) are generated by both prokaryotic and eukaryotic cells might have a profound effect on experimental and clinical sciences, and could pave the way for new strategies to combat various diseases. EVs are carriers of pathogen-associated and damage-associated molecular patterns, cytokines, autoantigens and tissue-degrading enzymes. In addition to a possible role in the pathogenesis of a number of inflammatory conditions, such as infections and autoimmune diseases, EVs, including microvesicles (also known as microparticles), exosomes and apoptotic vesicles, have therapeutic potential and might be used as biomarkers for inflammatory diseases. Therefore, molecular diagnostics and targeted therapy could benefit from expanding knowledge in the field. In this Review, we summarize important developments and propose that extracellular vesicles could be used as therapeutic vehicles and as targets for the treatment and prevention of inflammatory diseases.
亚微米大小的细胞外囊泡(EVs)不仅存在于真核细胞中,也存在于原核细胞中,这一发现可能会对实验和临床科学产生深远的影响,并为治疗各种疾病开辟新的策略。EVs 是病原体相关和损伤相关分子模式、细胞因子、自身抗原和组织降解酶的载体。除了在多种炎症性疾病(如感染和自身免疫性疾病)的发病机制中可能发挥作用外,EVs(包括微囊泡(也称为微颗粒)、外泌体和凋亡囊泡)具有治疗潜力,并且可能作为炎症性疾病的生物标志物。因此,分子诊断和靶向治疗可能受益于该领域知识的扩展。在这篇综述中,我们总结了重要的进展,并提出细胞外囊泡可用作治疗载体,以及治疗和预防炎症性疾病的靶点。